Literature DB >> 1564678

A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive.

C A Graham1, B B Sherwin.   

Abstract

Eighty-two women with complaints of moderate to severe premenstrual symptoms were recruited for a double-blind, controlled trial of a triphasic oral contraceptive (o.c.). Subjects made daily ratings of symptoms for at least one baseline cycle and were then randomly assigned to receive either placebo or o.c. for three months. Twenty-three women dropped out of the study (18 o.c., 5 placebo), 13 failed to show prospective confirmation of moderate to severe premenstrual symptoms, and one placebo subject had an anovulatory cycle. Forty-five women with prospectively-confirmed premenstrual changes (20 o.c., 25 placebo) completed the study. Premenstrual breast pain and bloating were significantly reduced with active treatment compared to placebo (p less than 0.03) but there were no beneficial effects of the o.c. over placebo for any of the mood symptoms. Women who received o.c.s reported decreased sexual interest after starting treatment and this effect was independent of any adverse influence on mood.

Entities:  

Keywords:  Abdominal Cramps; Acne; Americas; Appetite Alterations; Behavior; Biology; Canada; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Control Groups; Depression; Dermatitis; Developed Countries; Diseases; Dizziness; Double-blind Studies; Dropout Characteristics; Dropouts; Edema; Emotions; Ethinyl Estradiol; Family Planning; Family Planning Programs; Fatigue; Headache; Human Volunteers; Mammary Gland Effects; Menstruation Disorders; Mental Disorders; Nausea; Nervousness; Norethindrone; North America; Northern America; Oral Contraceptives; Oral Contraceptives, Combined; Oral Contraceptives, Phasic; Pain; Physiology; Premenstrual Tension; Prospective Studies; Psychological Factors; Research Methodology; Research Report; Signs And Symptoms; Studies

Mesh:

Substances:

Year:  1992        PMID: 1564678     DOI: 10.1016/0022-3999(92)90090-o

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  25 in total

Review 1.  Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial.

Authors:  Tory A Eisenlohr-Moul; Susan S Girdler; Jacqueline L Johnson; Peter J Schmidt; David R Rubinow
Journal:  Depress Anxiety       Date:  2017-07-17       Impact factor: 6.505

3.  Psychological, social, and spiritual effects of contraceptive steroid hormones.

Authors:  Hanna Klaus; Manuel E Cortés
Journal:  Linacre Q       Date:  2015-08

4.  Premenstrual dysphoric disorder: burden of illness and treatment update.

Authors:  Teri Pearlstein; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

5.  Premenstrual syndrome. Evidence-based treatment in family practice.

Authors:  Sue Douglas
Journal:  Can Fam Physician       Date:  2002-11       Impact factor: 3.275

Review 6.  Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?

Authors:  Uriel Halbreich; P M Shaughn O'Brien; Elias Eriksson; Torbjörn Bäckström; Kimberly A Yonkers; Ellen W Freeman
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 7.  Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management.

Authors:  M Steiner
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

Review 8.  Hormone treatment of depression.

Authors:  Russell T Joffe
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

9.  Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States.

Authors:  Katherine M Keyes; Keely Cheslack-Postava; Carolyn Westhoff; Christine M Heim; Michelle Haloossim; Kate Walsh; Karestan Koenen
Journal:  Am J Epidemiol       Date:  2013-09-15       Impact factor: 4.897

10.  Differences in free estradiol and sex hormone-binding globulin in women with and without premenstrual dysphoric disorder.

Authors:  Susan Thys-Jacobs; Don McMahon; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2007-10-23       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.